STOCK TITAN

Ginkgo Bioworks Holdings Inc - DNA STOCK NEWS

Welcome to our dedicated news page for Ginkgo Bioworks Holdings (Ticker: DNA), a resource for investors and traders seeking the latest updates and insights on Ginkgo Bioworks Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ginkgo Bioworks Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ginkgo Bioworks Holdings's position in the market.

Rhea-AI Summary
Alveolus Bio (ALVB) announced a strategic scientific collaboration with BiomEdit, an animal health biotechnology company leveraging microbiome science and synthetic biology to develop novel products to prevent and treat disease in animals. The collaboration aims to study BiomEdit's proprietary consortium of commensal strains with anti-inflammatory and immune-modulating properties, as well as to explore the application of Alveolus Bio's resMIT platform for the development of respiratory therapeutics in companion animals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.26%
Tags
none
-
Rhea-AI Summary
Alveolus Bio (ALVB) announced a strategic scientific collaboration with BiomEdit, an animal health biotechnology company leveraging microbiome science and synthetic biology to develop novel products to prevent and treat disease in animals. The collaboration aims to study BiomEdit's proprietary consortium of commensal strains with anti-inflammatory and immune-modulating properties, as well as to explore the application of Alveolus Bio's resMIT platform for the development of respiratory therapeutics in companion animals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.23%
Tags
none
-
Rhea-AI Summary
Agrivalle (NYSE: DNA) partners with Ginkgo Bioworks to advance biological products. Ginkgo's advanced biology tools will optimize Agrivalle's biocontrol products, improve crop nutrition, and target pests. Brazil's growing biologicals market presents a significant opportunity for the partnership to provide sustainable alternatives to pest control products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.26%
Tags
partnership
Rhea-AI Summary
Synplogen Co. (SYN) and Ginkgo Bioworks (NYSE: DNA) have entered into a non-binding MOU to accelerate the global development of DNA manufacturing and gene therapy platform services in Japan. Synplogen will support and introduce Ginkgo's gene therapy services within the Japanese biotechnology and pharmaceutical ecosystem. Ginkgo will explore global business collaboration opportunities for DNA manufacturing, while Synplogen plans to collaborate by offering business development and marketing support to connect Ginkgo's services with Japanese biotechnology and pharmaceutical companies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
none
-
Rhea-AI Summary
Vivici BV (DNA) partners with Ginkgo Bioworks to advance sustainable and nutritious dairy protein production through precision fermentation. The collaboration aims to leverage Ginkgo's Protein Production Services and AI platform to deliver optimized strains for dairy protein production, supporting Vivici's mission to provide planet-friendly nutrition to consumers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.79%
Tags
none
-
Rhea-AI Summary
Foremost Farms USA (NYSE: DNA) and Ginkgo Bioworks Partner to Upcycle Dairy Co-products into Value-Added Materials, Reducing Carbon Footprint and Lowering Manufacturing Costs
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.44%
Tags
none
Rhea-AI Summary
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) added 21 new Cell Programs to the Foundry platform in Q3 2023 and entered into a strategic cloud and AI partnership with Google Cloud. They also signed a new multi-target RNA drug discovery collaboration with Pfizer, with potential payments of up to $331 million. Ginkgo ended Q3 2023 with over $1.0 billion in cash and cash equivalents, maintaining a multi-year runway as they continue to drive towards profitability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.44%
Tags
earnings
-
Rhea-AI Summary
Ginkgo Bioworks (NYSE: DNA) will host a presentation and Q&A session on November 8, 2023, to review business performance for Q3 2023. The session will begin at 5:30 p.m. ET and will be available on Ginkgo's investor relations website. Questions can be submitted via Twitter or email.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
earnings
-
Rhea-AI Summary
Ginkgo Bioworks partners with Penn State University to integrate biosurveillance capabilities into research of 58 wildlife species for SARS-CoV-2. The initiative aims to monitor potential spillover to humans and prevent the spread of new variants. The research will provide data for informed decision-making by public health officials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.37%
Tags
partnership
Rhea-AI Summary
Ginkgo Bioworks and the Government of Serbia have entered into a Memorandum of Understanding to collaborate on Serbia's bioeconomy vision. They will establish a Startup Accelerator leveraging Ginkgo's platform to support Serbian companies building with biology. Serbia's BIO4 campus initiative aims to make Serbia a bioeconomy hub in Europe and has already signed MoUs with various companies. Ginkgo will offer flexible services to companies at BIO4 and explore partnerships to develop biomonitoring capabilities in Serbia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
none
Ginkgo Bioworks Holdings Inc

NYSE:DNA

DNA Rankings

DNA Stock Data

2.37B
1.12B
6.74%
83.72%
11.88%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Boston

About DNA

the organism company ginkgo bioworks engineers new organisms to solve challenges across a range of industries from fuels to pharmaceutical production. our biological engineers make use of an in-house pipeline of synthetic biology technologies to design, build, and test new organisms.